Arrowhead director plans $1.0M stock sale

ARROWHEAD PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael Perry has filed a notice of proposed sale of common stock under Rule 144. He plans to sell up to 11,600 shares of Arrowhead common stock through Merrill Lynch on NASDAQ, with an estimated aggregate market value of $1,012,171.97. The shares were acquired from the issuer as compensation on several dates in 2021, 2022, and 2025. Arrowhead had 141,254,467 shares outstanding of common stock; this is a baseline figure, not the amount being offered.

Key Figures

Shares proposed to be sold: 11,600 shares Aggregate market value of shares: $1,012,171.97 Shares outstanding: 141,254,467 shares +4 more

7 metrics

Shares proposed to be sold 11,600 shares Number of Arrowhead common shares listed for potential sale under Rule 144

Aggregate market value of shares $1,012,171.97 Estimated aggregate market value of the 11,600 shares proposed for sale

Shares outstanding 141,254,467 shares Arrowhead Pharmaceuticals common shares outstanding as referenced in the notice

Compensation shares 2025 grant 600 shares Common shares acquired as compensation on 12/18/2025

Compensation shares 2022 grant 9,000 shares Common shares acquired as compensation on 01/01/2022

Compensation shares 2021 grant 2,000 shares Common shares acquired as compensation on 01/01/2021

Proposed sale date 08/18/2026 Approximate date of sale for the Rule 144 transaction

Key Terms

Rule 144, aggregate market value, compensation

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"11600 | 1012171.97 | 141254467 | 08/18/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

compensation financial

"Common | 12/18/2025 | Compensation | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ARWR?

The filing discloses that director Michael Perry plans to sell up to 11,600 ARWR common shares under Rule 144, with an estimated aggregate market value of $1,012,171.97, through Merrill Lynch on NASDAQ.

How many Arrowhead Pharmaceuticals (ARWR) shares are proposed to be sold?

Michael Perry has noticed a proposed sale of 11,600 shares of Arrowhead Pharmaceuticals common stock. These shares correspond to awards acquired as compensation on multiple grant dates in 2021, 2022, and 2025.

What is the estimated value of the ARWR shares Michael Perry plans to sell?

The proposed sale covers shares with an aggregate market value of $1,012,171.97. This estimate relates specifically to the 11,600 shares identified for potential sale under Rule 144 through Merrill Lynch.

How were the ARWR shares that may be sold by Michael Perry acquired?

The shares were acquired from Arrowhead Pharmaceuticals as compensation. They are broken down as 600 shares (12/18/2025), 9,000 shares (01/01/2022), and 2,000 shares (01/01/2021), totaling 11,600 shares.

How does the proposed sale size compare to Arrowhead Pharmaceuticals’ (ARWR) shares outstanding?

Arrowhead Pharmaceuticals had 141,254,467 shares outstanding of common stock. The proposed 11,600-share sale by Michael Perry relates only to his holdings and does not represent the total shares outstanding.

Who is the broker for the proposed ARWR stock sale under Form 144?

The proposed sale of 11,600 ARWR shares is listed with Merrill Lynch, located at 75 Rockefeller Plaza, New York. The shares are intended to be sold on NASDAQ under Rule 144, subject to applicable conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:25 PM Accepted by SEC EDGAR 08/18/2026 - 05:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001250379
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arrowhead Pharmaceuticals Inc.
SEC File Number	001-38042
Address of Issuer	177 E. Colorado Blvd Ste 700 Pasadena CALIFORNIA 91105
Phone	6263043400
Name of Person for Whose Account the Securities are To Be Sold	Michael Perry
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 75 Rockefeller Plz 2nd Flr New York NY 10019	11600	1012171.97	141254467	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/18/2025	Compensation	Issuer			600	12/18/2025	Compensation
Common	01/01/2022	Compensation	Issuer			9000	01/01/2022	Compensation
Common	01/01/2021	Compensation	Issuer			2000	01/01/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Michael Perry
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)